Advertisement

Topics

Latest Biotechnology Products NewsRSS

07:02 EDT 29th March 2017 | BioPortfolio

Schnell Biopharmaceuticals Inc 003060 Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

SummarySchnell Biopharmaceuticals Inc Schnell, formerly Korea Schnell Pharma Co., Ltd. is a healthcare company that offers agents and antibiotics. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising ...

Eleven Biotherapeutics: Taking on ADCs with targeted protein therapeutics

A two-step manufacturing process makes antibody-drug conjugate production expensive and causes stability issues, says Eleven Biotherapeutics which is fusing antibody fragments to cytotoxic proteins.

Immune-Onc Therapeutics, Inc. Announces Licensing and Collaboration With Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center to Develop Novel Cancer Immunotherapy

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a newly established biopharmaceutical company focused on advancing promising immuno-oncology therapeutics, announced today that it has entered into an exclusive worldwide license agreement with Albert Einstein College of Medicine (“Einstein”) and Memorial Sloan Kettering Cancer Center (“MSK”). ...

LabKey Releases Software Solution for Accelerating Large Molecule Development

Designed in partnership with the pharma & biotech community, LabKey Biologics aims to streamline biotherapeutic research operations SEATTLE, WA (PRWEB) March 28, 2017 LabKey and collaborator Just Biotherapeutics, Inc. (Just) are excited to announce the initial release of LabKey’s newest software solution, LabKey Biologics. Built in collaboration with Just and designed with input from an adv...

Oxford BioTherapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

SummaryOxford BioTherapeutics Ltd Oxford BioTherapeutics is a biotechnology company that develops antibody drug conjugates ACDs for the treatment of variety of cancers. The company's OGAP technology is used to define the best targets for the development of ADCs. It also provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies. The OGAP platform o...

Ipsen Biopharmaceuticals Joins National Pharmaceutical Council

WASHINGTON, March 28, 2017 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, Inc. has joined the health policy research organization as its newest member. David Cox, PhD, Vice President, Medical and Regulatory Affairs (North America), will serve as his company's representative on NPC's Board of Directors. "We're pleased to...

Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

BOTHELL, Wash., March 28, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16th Annual Needham Healthcare Conference at 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, April 4, 2017 in New York, NY. The presentation will fe...

ImMAGE Biotherapeutics' DNA immunotherapy shows high efficacy with low toxicology results

BETHESDA, Md., March 27, 2017 /PRNewswire-USNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced today that its immunotherapy successfully passed early toxicology and efficacy studies. The company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to find a better treatment for triple negative breast ...

Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

Single-agent and Combination Data Support Clinical Development Plan Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that it will present preclinical data supporting the ongoing developmen...

Formycon (FYB) - Surfing the next wave of biosimilars

Edison Investment Research - Pharmaceutical & healthcare - Formycon: Formycon is a pure-play biosimilar company focused on third-wave biosimilars (those coming off patent after 2020), an overlooked opportunity for most biosimilar developers. The company has four compounds, two of which are partnered. FYB201 is a biosimilar of Lucentis for neovascular age-related macular degeneration (nAMD) undergo...

XLprotein GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 27022017] Prices from USD $250

SummaryXLprotein GmbH XLprotein is a biotechnology company that offers development of second generation biopharmaceuticals. The company commercializes PASylation technology, designed to enable the biopharmaceuticals drug development with extended plasma halflife and enhanced action. It provides chemical conjugation of therapeutic proteins with polyethylene glycol to extend size. XLprotein offers c...

How These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences

NEW YORK, March 27, 2017 /PRNewswire/ -- Pre-market today, Stock-Callers.com has initiated reports coverage on Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM), Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Neuralstem Inc. (NASDAQ: CUR), and Aptose Biosciences Inc. (NASDAQ: APTO). According to an article of ETF Trends, the iShares Nasdaq Biotechnology ETF is higher by nearly 12% this year, a s...

TaiGen Biotechnology and HEC Pharmaceutical Executed Equity Purchase Agreement for Their HCV Joint Venture

TAIPEI, Taiwan, March 27, 2017 /PRNewswire/ -- TaiGen Biotechnology Co., Ltd. ("TaiGen") announced today that its wholly owned subsidiary, TaiGen Biopharmaceuticals Co. (Beijing), Ltd. ("TGBJ") has executed an equity purchase agreement to sell its 9% equity stake in Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. ("Dongguan"), a joint venture company between TGBJ and HEC, to YiChang HEC ChangJian...

Speaker: Biosimilars offer opportunity for increased patient access

NEW YORK CITY — Biosimilars are highly similar to their respective reference products and are currently priced about 15% less, according to a presenter here at the Interdisciplinary Autoimmune Summit.“With many biopharmaceuticals going off-patent in the near future, opportunity exists to expand patient access through availability of biosimilars,” Jonathan Kay, MD, said.

XTL Biopharmaceuticals Ltd XTLB Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryXTL Biopharmaceuticals Ltd XTL is a biopharmaceutical company that offers acquisition, development and commercialization of pharmaceutical products and formulations. The company's pipeline products comprise hCDR1 peptide and recombinant erythropoietin rHuEPO. Its hCDR1 peptide is used for the treatment of systemic lupus erythematosus SLE; and rHuEPO is a compound developed to prolongate mul...

Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer

WESTLAKE VILLAGE, Calif., March 24, 2017 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as Chief Financial Officer, effective March 24.   Peterson, who brings more than two decades of global financial experience, will succeed John Smither, w...

FDA extends comment period for interchangeability guidance

In a Federal Register notice published on 15 March 2017 the US Food and Drug Administration (FDA) announced that it would be extending the comment period on its draft guidance on the interchangeability of biosimilars with their reference biologicals. This change came after the agency received requests for an extension. 

Study of top-down infliximab use in children with Crohn’s disease

The Erasmus Medical Center, in collaboration with the Netherlands Organisation for Health Research and Development and biosimilars maker Hospira, now Pfizer, is carrying out a study to investigate the benefits and risks of the use of infliximab as first-line use for children with active perianal fistulising Crohn’s disease [1].

Evidence on biosimilar efficacy and safety leads to ASAS/EULAR recommendation

A study of biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) found no reason for physicians not to prescribe infliximab biosimilars [1].

Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment

KNOXVILLE, Tenn., March 23, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today disclosed terms of the previously announced Definitive Financing Commitment Term Sheet (the "Definitive Financing") it entered into on March 19 with a group of the Comp...

Therapure Biomanufacturing Receives 2017 CMO Leadership Individual Attribute Awards for Capabilities and Staff Characteristics

Therapure Biomanufacturing, the contract development and manufacturing division of Therapure Biopharma Inc., announces that it has received The CMO Leadership Individual Attribute awards in four areas: Strength of Science, State of the Art, Accessible Senior Management and Cultural Fit. The Life Science Leader’s annual CMO Leadership Awards Ceremony ...

NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

BETHESDA, Md., March 23, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017. The Company sold to several institutional investors securities totaling 28,843,692...

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

PALO ALTO, Calif., March 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months and full year ended December 31, 2016. "We believe that 2016, Eiger's first year as a publicly traded company, was a year of s...

Vaxil BioTherapeutics Secures Collaboration With For Its Lead Product

  Life Sciences Jobs   ...

Lisa Holst Joins NorthStar Medical Radioisotopes as Vice President of Sales and Marketing

NorthStar Medical Radioisotopes LLC has hired Lisa Holst as vice president of sales and marketing. Holst has more than 25 years of sales and marketing experience in the pharmaceutical and medical imaging industries, most recently as senior director of marketing at Navidea B

Quick Search
Advertisement
 

review and buy Biotechnology Products market research data and corporate reports here